Novo Nordisk A/S - share repurchase programme
January 30, 2024 10:28 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 30 January 2024 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S - share repurchase programme
January 22, 2024 07:01 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 22 January 2024 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S - share repurchase programme
January 15, 2024 05:43 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 15 January 2024 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
January 09, 2024 11:15 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 9 January 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes
January 08, 2024 07:49 ET
|
Novo Nordisk A/S
COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in...
Novo Nordisk A/S - share repurchase programme
January 08, 2024 06:11 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 08 January 2024 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
January 04, 2024 05:59 ET
|
Novo Nordisk A/S
Omega collaboration will leverage the company’s platform to develop an epigenomic controller as part of a new approach to obesity managementCellarity collaboration will build upon initial work and...
Novo Nordisk A/S - share repurchase programme
December 22, 2023 06:52 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 22 December 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S - share repurchase programme
December 18, 2023 08:37 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 18 December 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S - share repurchase programme
December 11, 2023 08:27 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 11 December 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...